| Abstract | Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m(-2) day(-1) on days 1-3) and cisplatin (100 mg m(-2) day(-1) on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels >14 mg l(-1). Toxic effects were as expected and were non-life-threatening; no treatment interruption was required. |
| Authors | R Bonacci, A Gigliotti, E Baudin, N Wion-Barbot, P Emy, M Bonnay, A F Cailleux, I Nakib, M Schlumberger, Réseau Comète
(Affiliation: Institut Gustave Roussy, Villejuif, France.)
|
| Journal | British journal of cancer
(Br J Cancer)
Vol. 78
Issue 4
Pg. 546-9
(Aug 1998)
ISSN: 0007-0920 SCOTLAND |
| PMID | 9716042
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Cisplatin
- Etoposide
- Mitotane
|
| Topics |
- Adrenal Cortex Neoplasms
(drug therapy)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma
(drug therapy)
- Cisplatin
(administration & dosage, adverse effects)
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Male
- Middle Aged
- Mitotane
(therapeutic use)
- Treatment Outcome
|
